Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,960
Completed, industry sponsors, Infectious disease and vaccines, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,960
1,960 trials
Showing 1 to 25, recently updated first.
- Phase II Clinical Trial of PCV24 in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 MonthsPivotal-lookingCompleted
Reinovax Biologics Co., LTDIndustry
NCT07333352 · 480 participants · Start Sep 11, 2025 · Primary completion Apr 14, 2026
Drug: 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700); 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13) · For: Pneumococcal Infectious Disease
Sites: Changzhi, China; Yangquan, China; Yuncheng, China · 7 sites in all
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult ParticipantsPivotal-lookingCompleted
Sinovac Life Sciences Co., Ltd.Industry
NCT06939777 · 255 participants · Start Apr 28, 2025 · Primary completion Dec 8, 2025
Drug: SNA02-48; Placebo and 2 more · For: Tetanus
Sites: Hefei, China
- Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)Pivotal-lookingCompleted
Hipra Scientific, S.L.UIndustry
NCT05142514 · 629 participants · Start Nov 11, 2021 · Primary completion May 6, 2022
Drug: COVID-19 Vaccine HIPRA; Cominarty (Pfizer-BioNtech) · For: SARS-CoV-2 Infection
Sites: Hanoi, Vietnam
Hipra Scientific, S.L.UIndustry
NCT05305573 · 26 participants · Start Mar 25, 2022 · Primary completion Nov 14, 2023
Drug: COVID-19 Vaccine HIPRA 40 ug/dose; Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection · For: SARS-CoV-2 Infection
Sites: A Coruña, Spain; Madrid, Spain; Móstoles, Spain · 7 sites in all
- Safety and Immunogenicity of a Booster Vaccination With an Adapted VaccinePivotal-lookingCompleted
Hipra Scientific, S.L.UIndustry
NCT06181292 · 913 participants · Start Nov 15, 2023 · Primary completion Jun 17, 2024
Drug: PHH-1V81; Comirnaty Omicron XBB1.5 · For: SARS-CoV2 Infection
Sites: Badalona, Spain; Barcelona, Spain; Centelles, Spain · 10 sites in all
- A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.Pivotal-lookingCompleted
Hipra Scientific, S.L.UIndustry
NCT05303402 · 240 participants · Start May 12, 2022 · Primary completion Jan 9, 2024
Drug: PHH-1V · For: SARS CoV 2 Infection
Sites: Badalona, Spain; Barcelona, Spain; Girona, Spain · 6 sites in all
- A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19Pivotal-lookingCompleted
Hipra Scientific, S.L.UIndustry
NCT05981846 · 279 participants · Start Sep 4, 2023 · Primary completion Nov 3, 2023
Drug: BIMERVAX; SIIV · For: SARS CoV 2 Infection; Influenza, Human
Sites: A Coruña, Spain; Santiago de Compostela, Spain; Badalona, Spain · 8 sites in all
Hipra Scientific, S.L.UIndustry
NCT05142553 · 1,164 participants · Start Nov 15, 2021 · Primary completion May 29, 2023
Drug: COVID-19 Vaccine HIPRA; Cominarty (Pfizer-BioNtech) · For: SARS-CoV 2 Infection
Sites: Badalona, Spain; Barcelona, Spain; Girona, Spain · 10 sites in all
Hipra Scientific, S.L.UIndustry
NCT06234956 · 242 participants · Start Jun 8, 2023 · Primary completion Sep 9, 2025
Drug: BIMERVAX · For: SARS CoV 2 Infection
Sites: Barcelona, Spain; Centelles, Spain; Girona, Spain · 7 sites in all
Traws Pharma, Inc.Industry
NCT07157007 · 93 participants · Start Sep 16, 2025 · Primary completion Feb 16, 2026
Drug: Ratutrelvir (83-0060) non-randomised; Paxlovid and 1 more · For: COVID - 19
Sites: Tashkent, Uzbekistan
- A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in AdultsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT06182124 · 1,710 participants · Start Dec 20, 2023 · Primary completion May 12, 2026
Drug: Multivalent Pneumococcal Vaccine - Formulation 1; Multivalent Pneumococcal Vaccine - Formulation 2 and 4 more · For: Pneumococcal Disease
Sites: Doral, Florida; Miami Lakes, Florida; Stockbridge, Georgia · 17 sites in all
Janssen Sciences Ireland UCJohnson & Johnson (Janssen) (JNJ)
NCT02494986 · 48 participants · Start Jul 6, 2015 · Primary completion Aug 18, 2026
Drug: Rilpivirine · For: Human Immunodeficiency Virus Type 1
Sites: Porto, Portugal; Bloemfontein, South Africa; Dundee, South Africa · 8 sites in all
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06663436 · 200 participants · Start Nov 13, 2024 · Primary completion Oct 21, 2025
Drug: altSonflex1-2-3 Dose A; altSonflex1-2-3 Dose B and 3 more · For: Diarrhoea
Sites: Kericho, Kenya
Brii Biosciences LimitedIndustry
NCT06491563 · 150 participants · Start Aug 6, 2024 · Primary completion Aug 5, 2026
Drug: BRII-179; BRII-835 (VIR-2218) and 1 more · For: For Treatment of Chronic Hepatitis B Virus Infection
Sites: Beijing, China; Xiamen, China; Foshan, China · 12 sites in all
Brii Biosciences LimitedIndustry
NCT05970289 · 86 participants · Start Aug 22, 2023 · Primary completion Jul 16, 2025
Drug: PEG-IFNα; BRII-835 · For: Chronic Hepatitis B Virus Infection
Sites: Kingswood, Australia; Birtinya, Australia; Melbourne, Australia · 28 sites in all
Golden Biotechnology CorporationIndustry
NCT03625102 · 60 participants · Start Feb 12, 2018 · Primary completion Jun 16, 2023
Drug: Antroquinonol · For: HBV
Sites: Taichung, Taiwan
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03827798 · 248 participants · Start Feb 27, 2019 · Primary completion Dec 4, 2024
Drug: CFZ533; Placebo to CFZ533 and 9 more · For: Hidradenitis Suppurativa
Sites: Clearwater, Florida; Orange Park, Florida; Tampa, Florida · 36 sites in all
- Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μgPivotal-lookingCompleted
OsivaxIndustry
NCT05569239 · 2,891 participants · Start Sep 8, 2025 · Primary completion May 18, 2026
Drug: OVX836 480µg; Saline Solution · For: Influenza
Sites: Antwerp, Belgium; Ghent, Belgium; Mechelen, Belgium · 16 sites in all
- A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in AdultsPivotal-lookingCompleted
CyanVac LLCIndustry
NCT06742281 · 432 participants · Start Dec 5, 2024 · Primary completion Jun 15, 2026
Drug: CVXGA (CVXGA50); COMIRNATY® · For: COVID-19
Sites: Anniston, Alabama; Phoenix, Arizona; Chula Vista, California · 55 sites in all
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05412030 · 388 participants · Start Jun 16, 2022 · Primary completion Sep 18, 2025
Drug: AFX3772; Prevnar 13 and 1 more · For: Pneumonia, Bacterial; Pneumococcal Infections; Pneumonia, Pneumococcal
Sites: Jonesboro, Arkansas; Gardena, California; Los Angeles, California · 52 sites in all
- A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)Pivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT06508320 · 931 participants · Start Jul 15, 2024 · Primary completion Sep 25, 2025
Drug: mRNA-1083 · For: Influenza; SARS-CoV-2
Sites: Hialeah, Florida; Hollywood, Florida; Miami, Florida · 17 sites in all
- A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate VaccineCompleted
LimmaTech Biologics AGIndustry
NCT06615375 · 97 participants · Start Nov 12, 2024 · Primary completion Apr 14, 2026
Drug: Shigella4V2; Placebo · For: Shigellosis
Sites: Atlanta, Georgia; Baltimore, Maryland; Cincinnati, Ohio
- A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgePivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT05127434 · 36,814 participants · Start Nov 17, 2021 · Primary completion Jul 28, 2025
Drug: Placebo; mRNA-1345 · For: Respiratory Syncytial Virus
Sites: Birmingham, Alabama; Guntersville, Alabama; Huntsville, Alabama · 269 sites in all
- NE3107 in Adults With Neurological Symptoms of Long COVIDPivotal-lookingCompleted
BioVie Inc.Industry
NCT06847191 · 203 participants · Start Apr 29, 2025 · Primary completion Aug 6, 2026
Drug: NE3107; Placebo · For: Long COVID
Sites: Palo Alto, California; San Francisco, California; Aurora, Colorado · 20 sites in all
- A Study of S-892216 in Participants With COVID-19Pivotal-lookingCompleted
ShionogiIndustry
NCT06928051 · 282 participants · Start Jun 6, 2025 · Primary completion Sep 22, 2025
Drug: S-892216; Placebo · For: COVID-19
Sites: Hot Springs, Arkansas; Coconut Creek, Florida; Coral Gables, Florida · 57 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.